The Concept of Oligometastatic Disease in Gastric Cancer: Reality or Fiction?

Kassar, Serge; Samaha, Ramy; Aoun, Rany; Khoury, Michel; Kattan, Joseph

doi:10.2217/fon-2021-1315

Cited by 3 publications

(3 citation statements)

References 23 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The incidence of OMD varies depending on the type of tumors. It was hypothesized in the past that some cancers such as pancreatic adenocarcinoma and small-cell lung cancer, never present with an oligo-metastatic behavior; to date, an oligo-metastatic status has been reported in all cancers [ 19 , 20 , 21 , 22 , 23 , 24 , 25 , 26 , 27 , 28 , 29 , 30 , 31 , 32 ]. The incidence of OMD varies greatly among cancer types, ranging from extremely rape (such as SCLC where only a few case reports are described) [ 21 ] to 10–40% of HCC [ 25 , 26 ].…”

Section: Epidemiology Of Omdmentioning

confidence: 99%

Oligo-Metastatic Cancers: Putative Biomarkers, Emerging Challenges and New Perspectives

Ottaiano

Santorsola

Circelli³

et al. 2023

Cancers

View full text Add to dashboard Cite

Some cancer patients display a less aggressive form of metastatic disease, characterized by a low tumor burden and involving a smaller number of sites, which is referred to as “oligometastatic disease” (OMD). This review discusses new biomarkers, as well as methodological challenges and perspectives characterizing OMD. Recent studies have revealed that specific microRNA profiles, chromosome patterns, driver gene mutations (ERBB2, PBRM1, SETD2, KRAS, PIK3CA, SMAD4), polymorphisms (TCF7L2), and levels of immune cell infiltration into metastases, depending on the tumor type, are associated with an oligometastatic behavior. This suggests that OMD could be a distinct disease with specific biological and molecular characteristics. Therefore, the heterogeneity of initial tumor burden and inclusion of OMD patients in clinical trials pose a crucial methodological question that requires responses in the near future. Additionally, a solid understanding of the molecular and biological features of OMD will be necessary to support and complete the clinical staging systems, enabling a better distinction of metastatic behavior and tailored treatments.

show abstract

Section: Epidemiology Of Omdmentioning

confidence: 99%

Oligo-Metastatic Cancers: Putative Biomarkers, Emerging Challenges and New Perspectives

Ottaiano

Santorsola

Circelli³

et al. 2023

Cancers

View full text Add to dashboard Cite

show abstract

“…The late detection of gastric cancer often results in unfavorable outcomes, with liver metastasis being a frequent complication [5][6][7]. Between 5-14% of patients develop liver metastasis, and this rate rises to 13.5-30% among those undergoing radical surgery, leading to high mortality [8][9][10].…”

Section: Introductionmentioning

confidence: 99%

Development and validation of nomogram models for predicting overall survival and cancer-specific survival in gastric cancer patients with liver metastases: a cohort study based on the SEER database

Meng

2024

Am J Cancer Res

View full text Add to dashboard Cite

Objective: To establish nomogram models for predicting the overall survival (OS) and cancer-specific survival (CSS) of gastric cancer liver metastasis (GCLM) patients. Methods: Data from the Surveillance, Epidemiology, and End Results (SEER) database for 5,451 GCLM patients diagnosed between 2010 and 2015 were analyzed. The cohort was divided into a training set (3,815 cases) and an internal validation set (1,636 cases). External validation included 193 patients from the Fourth Hospital of Hebei Medical University and 171 patients from the People's Hospital of Shijiazhuang City, spanning 2016-2018. Multivariable Cox regression analysis identified eight independent prognostic factors for OS and CSS in GCLM patients, including age, histological type, grade, tumor size, surgery, chemotherapy, bone metastasis, and lung metastasis. Two nomogram models were developed based on these factors and evaluated using time-dependent receiver operating characteristic curve analysis, calibration curves, and decision curve analysis. Results: Internal validation showed that the nomogram models outperformed the American Joint Committee on Cancer (AJCC) tumor-node-metastasis (TNM) staging system in predicting 1-year, 2-year, and 3-year OS and CSS in GCLM patients (1-year OS: 0.801 vs. 0.593, P < 0.001; 1-year CSS: 0.807 vs. 0.598, P < 0.001; 2-year OS: 0.803 vs. 0.630, P < 0.001; 2-year CSS: 0.802 vs. 0.633, P < 0.001; 3-year OS: 0.824 vs. 0.691, P < 0.001; 3-year CSS: 0.839 vs. 0.692, P < 0.001). Conclusion: This study developed and validated nomogram models using SEER database data to predict OS and CSS in GCLM patients. These models offer improved prognostic accuracy over traditional staging systems, aiding in clinical decision-making.

show abstract

“…The incidence of oligo-metastases is influenced by the tumor's intrinsic biological characteristics, the patient's immune response, and the microenvironment of both the primary tumor and metastatic sites. Interestingly, while it was once hypothesized that certain cancers, such as pancreatic adenocarcinoma and small-cell lung cancer, never exhibited an oligo-metastatic behavior, current evidence indicates that OMD can be documented in all cancer types [4][5][6][7][8]. Notably, the incidence of "induced" OMD is rising across all cancers due to advancements in systemic treatments, including biologic drugs, immunotherapies, and integrated therapeutic approaches, which improve outcomes for primary poly-metastatic cancers.…”

Section: Introduction: Epidemiology and Definitions Of Oligo-metastasesmentioning

confidence: 99%

Oligo-Metastatic Disease in Oncology: Exploring the Limits and the Potential of Genetic Assessment

Santorsola,

Capuozzo,

Savarese

et al. 2023

Genes

View full text Add to dashboard Cite

Oligo-metastatic disease (OMD) in the field of oncology denotes a distinct subset of metastatic tumors characterized by less aggressive biological behavior and extended survival times in comparison to their widely metastatic counterparts. While there is a general consensus regarding the existence of OMD, there remains a lack of widely accepted criteria for its a priori identification at the time of presentation. This review delves into the concept of OMD, placing a particular emphasis on the significance of understanding the limitations and potential of genetic assessments. It explores how these aspects are crucial in advancing our comprehension of this phenomenon. In a rapidly advancing era of precision medicine, understanding the intricacies of OMD opens up exciting possibilities for tailored treatment approaches. By elucidating the genetic underpinnings and dynamic nature of this condition, we stand to improve patient outcomes and potentially shift the paradigm of metastatic cancer management.

show abstract

The Concept of Oligometastatic Disease in Gastric Cancer: Reality or Fiction?

Abstract: Positive results in the RENAISSANCE Trial will establish oligometastatic gastric cancer as a real independent entity where total surgical treatment will become the standard of care.

Cited by 3 publications

References 23 publications

Oligo-Metastatic Cancers: Putative Biomarkers, Emerging Challenges and New Perspectives

Oligo-Metastatic Cancers: Putative Biomarkers, Emerging Challenges and New Perspectives

Development and validation of nomogram models for predicting overall survival and cancer-specific survival in gastric cancer patients with liver metastases: a cohort study based on the SEER database

Oligo-Metastatic Disease in Oncology: Exploring the Limits and the Potential of Genetic Assessment

Contact Info

Product

Resources

About